The studies were conducted with a formulation based on HemCon’s newest proprietary platform technology that provides a controlled release broad spectrum antifungal and antibacterial agent to fight infection.
Independent testing of HemCon’s topical formulation for the treatment of onychomycosis was analyzed by MedPharm using its TurChub test system. This system tests the penetration of human nails by the test substance and subsequent killing of the fungal infection underneath.
HemCon’s formulation was evaluated against two onychomycosis treatments. The HemCon formulation successfully penetrated the nail and killed the infection to a significantly greater extent than the other treatments. In a second, human-based study, safety results indicated that no skin irritation was seen from the topical formulations of HemCon’s onychomycosis treatment.
John Morgan, CEO of HemCon, said: “These studies confirm the promise of our new treatment, which has the potential to offer effective relief for the 40 million Americans afflicted with fungal nail infections. As HemCon continues to pioneer new products that promote safe, effective healing, our solutions will also positively impact high demand markets like fungal treatment. These impressive test results will allow us to further develop products based on this new platform and offer them on a global scale.”